CatalystMarker
Sign in
← board

ABBV

AbbViedistress 2/10 · well-funded / low risk
$255.33+1%today-2% from 52w high
abbvie.com57,000 employeesFounded 2012North Chicago, ILDrug Manufacturers - General
Oncology 3Cardiovascular 1Dermatology 1Metabolic / Obesity 1Neurology 1Ophthalmology 1
Lead: Multiple Myeloma · est. market ~$25B (approx, global)
Revenue
$15002M
Liquidity
$9687M
Runway
—
Shares 1y
0%

Price & events

+18.9% over 6M
$196$228$259Jan 26Apr 26Jul 2652.6Mdilution: 424B5 offering (2026-02-26)dilution: FWP offering (2026-02-26)dilution: FWP offering (2026-02-25)dilution: 424B5 offering (2026-02-24)rating: Citigroup: Neutral (2026-07-15)rating: UBS: Neutral (2026-07-13)rating: BMO Capital: Outperform (2026-07-13)rating: B of A Securities: Buy (2026-07-10)rating: RBC Capital: Outperform (2026-07-10)rating: Wells Fargo: Overweight (2026-07-10)rating: Guggenheim: Buy (2026-07-09)rating: JP Morgan: Overweight (2026-07-09)
CatalystRating changeDilutionFinancingdashed = today
+0.8%
1D
+0.4%
1W
+9.5%
1M
+28.0%
3M
+18.3%
6M
+38.2%
1Y
+57.5%
2Y
+159.5%
5Y
+201.3%
All

Overview

Market Cap
$451.12B
Enterprise Value
$506.23B
Volume
308.57K
52 Week Range
$185 – $261
Total Shares
1.77B
Float Shares
1.76B
Short %
1.38%
% Held by Insiders
0.11%
% Held by Institutions
76.85%
RVOL
0.04x
Beta
0.28

Pipeline stages · 27 programs

Upadacitinib, Dupilumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
Livmoniplimab, Budigalimab, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10
Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Icalcaprant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Etentamig, Lenalidomide, Daratumumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Lutikizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Ubrogepant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01
IMGN151, Carboplatin, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01
Risankizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-02
Show all 27 programs · 17 more ▾
Emraclidine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-02
Atogepant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03
Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03
Pivekimab Sunirine, Venetoclax, Azacitidine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04
Surabgene Lomparvovec, Sham, Topical Steroid
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06
AGN-193408 SR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09
XEN63 Glaucoma Treatment System
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11
GC012F Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-24
RGX-314
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12
Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01
NOA VOLUME, VOLUMA XC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-07
ELAPR002f Injectable Gel, Saline Control
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-11
Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-02
Lenvatinib, ABBV-324
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-09
ARTIA Reconstructive Tissue Matrix
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-02
Dexamethasone, Daratumumab, Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-05
25mg Eluxadoline, 100mg Eluxadoline
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-12

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-09
Estimated 50%
readout ~2027-11-15
Phase 3UpadacitinibCrohn's Disease—active not recruiting
2027-10
Estimated 50%
readout ~2027-10-31
Phase 1Livmoniplimab, BudigalimabHepatocellular Carcinoma (HCC)—recruiting
2027-11
Estimated 50%
readout ~2027-12-16
Phase 1/2Telisotuzumab Adizutecan, Budigalimab, PembrolizumabNon Small Cell Lung Carcinoma—recruiting
2027-11
Estimated 50%
readout ~2027-12-16
Phase 2IcalcaprantBipolar I Disorder, Bipolar II Disorder—recruiting
2027-11
Estimated 50%
readout ~2027-12-01
Phase 1ABBV-400, Trifluridine/Tipiracil, BevacizumabNon-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer—active not recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-11
Estimated 50%
readout ~2027-12-01
Phase 1ABBV-706, Cisplatin, BudigalimabAdvanced Solid Tumors—active not recruiting
2027-12
Estimated 50%
readout ~2028-01-15
Phase 2LutikizumabHidradenitis Suppurativa—active not recruiting
2027-12
Estimated 50%
readout ~2028-02-14
Phase 3Etentamig, Carfilzomib, PomalidomideMultiple Myeloma—recruiting
2027-12
Estimated 50%
readout ~2028-01-15
Phase 2Lutikizumab, RisankizumabPsoriatic Arthritis—recruiting
2027-12
Estimated 50%
readout ~2027-12-31
Phase 1Telisotuzumab AdizutecanColorectal Cancer—active not recruiting
2028-01
Estimated 50%
readout ~2028-03-16
Phase 3UbrogepantMigraine—enrolling by invitation
2028-01
Estimated 50%
readout ~2028-02-15
Phase 2IMGN151, Carboplatin, BevacizumabGynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)—recruiting
2028-02
Estimated 50%
readout ~2028-03-17
Phase 1/2ABBV-383 (Etentamig)Immunoglobulin Light Chain (AL) Amyloidosis—recruiting
2028-02
Estimated 50%
readout ~2028-03-17
Phase 2Telisotuzumab VedotinNon-Small Cell Lung Cancer—recruiting
2028-02
Estimated 50%
readout ~2028-03-17
Phase 2EmraclidineSchizophrenia—recruiting
2028-02
Estimated 50%
readout ~2028-04-16
Phase 3Risankizumab, UstekinumabCrohn's Disease (CD)—active not recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3Telisotuzumab Vedotin, DocetaxelNon Small Cell Lung Cancer—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3Venetoclax, Acalabrutinib, ObinutuzumabChronic Lymphocytic Leukemia—recruiting
2028-03
Estimated 50%
readout ~2028-04-15
Phase 2Telisotuzumab Adizutecan, Fluorouracil, OxaliplatinMetastatic Colorectal Cancer—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3AtogepantEpisodic Migraine—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3UpadacitinibVitiligo—active not recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3UpadacitinibHidradenitis Suppurativa—recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3RisankizumabPsoriasis—active not recruiting
2028-04
Estimated 50%
readout ~2028-05-01
Phase 1Pivekimab SunirineAcute Myeloid Leukemia—recruiting
2028-06
Estimated 50%
readout ~2028-08-15
Phase 2/3Surabgene Lomparvovec, Sham, Topical SteroidDiabetic Retinopathy—recruiting
2028-07
Estimated 50%
readout ~2028-08-15
Phase 2VenetoclaxWaldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma—recruiting
2028-08
Estimated 50%
readout ~2028-10-15
Phase 3Upadacitinib, PrednisoloneTakayasu Arteritis (TAK)—active not recruiting
2028-08
Estimated 50%
readout ~2028-10-15
Phase 3UpadacitinibUlcerative Colitis—active not recruiting
2028-09
Estimated 50%
readout ~2028-10-16
Phase 2AGN-151607-DPVentral Hernia—recruiting
2028-09
Estimated 50%
readout ~2028-11-15
Phase 3risankizumabUlcerative Colitis (UC)—active not recruiting
2028-11
Estimated 50%
readout ~2029-01-15
Phase 3XEN63 Glaucoma Treatment SystemPrimary Open Angle Glaucoma—recruiting
2028-11
Estimated 50%
readout ~2028-12-16
Phase 2AGN-151607-DPUpper Limb Essential Tremor—recruiting
2028-11-24
Estimated 50%
readout ~2028-12-24
Phase 1GC012F InjectionRelapsed/Refractory AL Amyloidosis—recruiting
2028-12
Estimated 50%
readout ~2029-01-15
Phase 2RGX-314Neovascular Age-related Macular Degeneration, Wet Macular Degeneration—enrolling by invitation
2029-01
Estimated 50%
readout ~2029-02-15
Phase 2Mirvetuximab Soravtansine, Bevacizumab, CarboplatinOvarian Cancer—recruiting
2029-01
Estimated 50%
readout ~2029-01-31
Phase 1ABBV-901, BevacizumabOvarian Cancer—recruiting
2029-02
Estimated 50%
readout ~2029-04-17
Phase 3UpadacitinibAlopecia Areata—recruiting
2029-04
Estimated 50%
readout ~2029-05-01
Phase 1ABBV-711, BudigalimabAdvanced Squamous Tumors—recruiting
2029-04
Estimated 50%
readout ~2029-05-16
Phase 1/2AGN-193408 SROpen-angle Glaucoma, Ocular Hypertension—active not recruiting
2029-04
Estimated 50%
readout ~2029-06-15
Phase 3RisankizumabCrohn's Disease—recruiting
2029-05
Estimated 50%
readout ~2029-06-15
Phase 2VenetoclaxChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)—recruiting
2029-05
Estimated 50%
readout ~2029-06-15
Phase 2ABBV-706, Atezolizumab, EtoposideSmall Cell Lung Cancer—recruiting
2029-05
Estimated 50%
readout ~2029-07-15
Phase 3Telisotuzumab adizutecan, Bevacizumab, Trifluridine/TipiracilColorectal Cancer—recruiting
2029-06
Estimated 50%
readout ~2029-08-15
Phase 3Upadacitinib, TocilizumabJuvenile Idiopathic Arthritis—recruiting
2029-07
Estimated 50%
readout ~2029-07-31
Phase 1ABBV-525Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma—active not recruiting
2029-07
Estimated 50%
readout ~2029-09-14
Phase 3NOA VOLUME, VOLUMA XCMid Face Volume Deficit—recruiting
2029-08
Estimated 50%
readout ~2029-08-31
Phase 1Etentamig (ABBV-383)Multiple Myeloma—recruiting
2029-09
Estimated 50%
readout ~2029-10-16
Phase 2ABBV-142Idiopathic Pulmonary Fibrosis—recruiting
2029-10
Estimated 50%
readout ~2029-11-15
Phase 1/2ABBV-6628, SYFOVREGeographic Atrophy, Age-Related Macular Degeneration—recruiting
2029-11
Estimated 50%
readout ~2030-01-15
Phase 3ELAPR002f Injectable Gel, Saline ControlAcne Scars—recruiting
2029-11
Estimated 50%
readout ~2029-12-16
Phase 2Telisotuzumab AdizutecanColorectal Cancer—recruiting
2030-01
Estimated 50%
readout ~2030-02-15
Phase 2Risankizumab, Lutikizumab, TrosunilimabCrohn's Disease—recruiting
2030-02
Estimated 50%
readout ~2030-03-18
Phase 2Carboplatin, Mirvetuximab Soravtansine, BevacizumabEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant—recruiting
2030-04
Estimated 50%
readout ~2030-05-16
Phase 1/2ABBV-1758Alzheimer's Disease—recruiting
2030-04
Estimated 50%
readout ~2030-06-15
Phase 3UpadacitinibAlopecia Areata—recruiting
2030-07
Estimated 50%
readout ~2030-09-14
Phase 3Upadacitinib, DupilumabAtopic Dermatitis—recruiting
2030-09
Estimated 50%
readout ~2030-11-15
Phase 2/3Telisotuzumab AdizutecanNon-Small Cell Lung Cancer—recruiting
2030-09
Estimated 50%
readout ~2030-11-15
Phase 3ABBV-706, Topotecan, LurbinectedinSmall Cell Lung Cancer—not yet recruiting
2030-09
Estimated 50%
readout ~2030-11-15
Phase 2/3Livmoniplimab, Budigalimab, DurvalumabHepatocellular Carcinoma—recruiting
2030-09
Estimated 50%
readout ~2030-10-01
Phase 1Lenvatinib, ABBV-324Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer—recruiting
2030-10
Estimated 50%
readout ~2030-11-15
Phase 2Telisotuzumab Adizutecan, Budigalimab, FluorouracilLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma—recruiting
2030-12
Estimated 50%
readout ~2031-01-15
Phase 2Telisotuzumab AdizutecanSolid Tumors Harboring MET Amplification—recruiting
2030-12
Estimated 50%
readout ~2031-01-15
Phase 1/2ABBV-453, Daratumumab, DexamethasoneMultiple Myeloma—recruiting
2031-02
Estimated 50%
readout ~2031-04-17
Phase 3ARTIA Reconstructive Tissue MatrixBreast Reconstruction—recruiting
2031-03
Estimated 50%
readout ~2031-05-15
Phase 3AtogepantChronic Migraine—recruiting
2031-03
Estimated 50%
readout ~2031-03-31
Phase 1ABBV-101, VenetoclaxHematologic Cancer—active not recruiting
2031-05
Estimated 50%
readout ~2031-06-15
Phase 2Dexamethasone, Daratumumab, VenetoclaxMultiple Myeloma—active not recruiting
2031-06
Estimated 50%
readout ~2031-08-15
Phase 2/3Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ LeucovorinaMetastatic Pancreatic Ductal Adenocarcinoma, PDAC—recruiting
2031-10
Estimated 50%
readout ~2031-12-15
Phase 2/3Livmoniplimab, Budigalimab, PembrolizumabNon-Small Cell Lung Cancer—recruiting
2031-11
Estimated 50%
readout ~2031-12-01
Phase 1ABBV-438Multiple Myeloma—recruiting
2031-12
Estimated 50%
readout ~2032-02-14
Phase 2/3Telisotuzumab Adizutecan, Osimertinib (Osi), CisplatinNon-Squamous Non-Small Cell Lung Cancer—recruiting
2032-04
Estimated 50%
readout ~2032-06-15
Phase 3AtogepantMigraine Prophylaxis—enrolling by invitation
2032-06
Estimated 50%
readout ~2032-08-15
Phase 2/3Pivekimab Sunirine, Venetoclax, AzacitidineAcute Myeloid Leukemia—not yet recruiting
2032-12
Estimated 50%
readout ~2033-02-14
Phase 325mg Eluxadoline, 100mg EluxadolineIrritable Bowel Syndrome—enrolling by invitation
2033-03
Estimated 50%
readout ~2033-05-15
Phase 3Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab ControlNeovascular Age-related Macular Degeneration—recruiting
2033-09
Estimated 50%
readout ~2033-10-01
Phase 1Etentamig, Dexamethasone, LenalidomideRelapsed/Refractory Multiple Myeloma—active not recruiting
2034-07
Estimated 50%
readout ~2034-09-14
Phase 3RisankizumabUlcerative Colitis—recruiting
2036-02
Estimated 50%
readout ~2036-03-17
Phase 1/2Etentamig, Lenalidomide, DexamethasoneMultiple Myeloma—recruiting
2036-03
Estimated 50%
readout ~2036-03-31
Phase 1Etentamig, IberdomideMultiple Myeloma—recruiting
2042-01
Estimated 50%
readout ~2042-03-17
Phase 2/3Etentamig, Lenalidomide, DaratumumabMultiple Myeloma—recruiting

Catalyst news & presentations · 2

Approved drugs (14)

  • DECNUPAZPIVEKIMAB SUNIRINE-PVZY2026 · Prescription
  • EMRELISTELISOTUZUMAB VEDOTIN-TLLV2025 · Prescription
  • EMBLAVEOAVIBACTAM SODIUM2025 · Prescription
  • VYALEVFOSCARBIDOPA2024 · Prescription
  • RINVOQ LQUPADACITINIB2024 · Prescription
  • SKYRIZIRISANKIZUMAB-RZAA2022 · Prescription
  • VUITYPILOCARPINE HYDROCHLORIDE2021 · Discontinued
  • QULIPTAATOGEPANT2021 · Prescription
  • MAVYRETGLECAPREVIR2021 · Prescription
  • ORIAHNN (COPACKAGED)ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE2020 · Prescription

Capital structure — dilution & financing

Shares out: 1,766,792,821 · 4 offerings/1y · 0 PIPEs
  • 2026-02-26FWPoffering
  • 2026-02-26424B5offering
  • 2026-02-25FWPoffering
  • 2026-02-24424B5offering
  • 2025-02-20424B5offering
  • 2025-02-19FWPoffering
  • 2025-02-18424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $267 (+4% upside) · 28 analysts
  • 2026-07-15CitigroupNeutral
  • 2026-07-13UBSNeutral
  • 2026-07-13BMO CapitalOutperform
  • 2026-07-10B of A SecuritiesBuy
  • 2026-07-10RBC CapitalOutperform
  • 2026-07-10Wells FargoOverweight

Competitors — Multiple Myeloma

  • JNJJOHNSON & JOHNSON$617.4B · D0
  • GSKGSK plc$217.0B · D1
  • PFEPFIZER INC$142.2B · D3
  • BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • CCCCC4 Therapeutics, Inc.$408M · D5
  • DTILPRECISION BIOSCIENCES INC$185M · D6
  • CRBUCaribou Biosciences, Inc.$160M · D0
  • TPSTTempest Therapeutics, Inc.$14M · D10
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.